Results of clinical phase III study of once-monthly aripiprazole IM depot formulation for the treatment of schizophrenia presented at APA
7 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced results from a clinical phase III clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia. Trial results were presented in four poster presentations at…